About us
Mission and values
Corporate responsibility
History
Products & Services
Efficacy / Models
General Toxicology
Safety Pharmacology / Telemetry
Genetic Toxicology
Reproduction & Fertility
Carcinogenicity
Ecotoxicology
Specializations
Drug Metabolism and Pharmacokinetcs
Bio/Analytical Chemistry
Biological Control / Potency Tests
Derek
REACH
Support
Animal Welfare
Events
Trade shows
Corporate Events
Career
Career Opportunities
Career Management & Training
Employee Benefits
Visit our main locations
Canada
Denmark
France
Hungary
Events
SOT 2011, Washington, DC
More Info
Seminar: A Battery of Toxicity Screening Assays for Selection of Dermal Drug Candidates
More Info
More trade shows
More corporate events
Home
Contact Us
News
Français
Fact Sheet
Q2 2010 Highlights
Revenue
of $15.2 million
Net loss
of $1.8 million
Net loss per share
of $0.03
Backlog
of $25.7 million
Investor Information
TSX Symbol:
LRI
Shares Outstanding: 52.7M
Fully Diluted: 58.2M
Market Cap. June 1, 2010: approx. $16.0 M.
Year-end: December 31st
Ownership
Management: 3%
Institutions: ≈ 70%
Retail: ≈ 27%
Management Team
Luc Mainville, President and CEO
Alain Tanguay, CFO
Andy Makin, Managing Director, Denmark
Christopher Banks, Managing Director, Hungary
2009 Highlights
$53.3 million revenue
$10.4 million net loss
$0.39 loss per share
Stay In Touch
Subscribe to E-News
RSS Feed
LinkedIn
Customer service
1-888-353-2240
Resource center
Inquiry form
Client center
Terms of Use
|
Contact
|
Site Map
Top of page
Français
|
Home
|
About
|
Careers
|
Corporate Profile
|
Products
|
Animal Welfare
|
Events
|
Customers Services
Copyright © 2006 LAB Research Inc. All Rights Reserved |
Data Privacy Policy